Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02471833 · ClinicalTrials.gov registry record · Phase 1
Health Evaluation in African Americans Using RAS Therapy
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT02471833 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 61 participants.
The verdict
NCT02471833, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if telmisartan, an FDA approved blood pressure medication, may also have beneficial effects on Alzheimer's disease prevention in African Americans, who are at high risk for Alzheimer's disease.
Interventions
- DRUG Placebo
- DRUG Telmisartan 20mg
- DRUG Telmisartan 40mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2015-04 |
| Est. Completion | 2022-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02471833
The ClinicalTrials.gov registry entry for NCT02471833 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02471833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02471833 about?
NCT02471833 is a clinical study titled "Health Evaluation in African Americans Using RAS Therapy". The purpose of this study is to determine if telmisartan, an FDA approved blood pressure medication, may also have beneficial effects on Alzheimer's disease prevention in African Americans, who are at high risk for Alzheimer's disease.
What is the current status of trial NCT02471833?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2015-04. Estimated completion is 2022-04-15.
What interventions are being tested in trial NCT02471833?
The interventions under investigation include: Placebo (DRUG), Telmisartan 20mg (DRUG), Telmisartan 40mg (DRUG).
Who is sponsoring clinical trial NCT02471833?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.